We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
+11.66%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.77B
AUM Growth
-$63.7M
(-3.5%)
Cap. Flow
-$1.85M
Cap. Flow
% of AUM
-0.1%
Top 10 Holdings %
Top 10 Hldgs %
78.21%
Holding
42
New
–
Increased
2
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marker Therapeutics
MRKR
|
+$1.96M |
| 2 |
Oric Pharmaceuticals
ORIC
|
+$606K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVRx
CVRX
|
+$4.25M |
| 2 |
MYND
Mynd.ai
MYND
|
+$165K |
| 3 |
OKUR
OnKure Therapeutics
OKUR
|
+$15 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.86% |
| 2 | Technology | 7.19% |
| 3 | Consumer Staples | 6.17% |
| 4 | Communication Services | 0.58% |
| 5 | Industrials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACLX
1
DELISTED
Arcellx
ACLX
| $287M | 16.21% |
3,745,262
| – | – |
|
|
VRNA
2
DELISTED
Verona Pharma
VRNA
| $259M | 14.64% |
5,584,753
| – | – |
|
|
TEM
3
Tempus AI
TEM
$7.6B
| $182M | 10.26% |
5,385,979
| – | – |
|
4
Rhythm Pharmaceuticals
RYTM
$7.34B
| $163M | 9.19% |
2,909,956
| – | – |
|
5
NextNav
NN
$1.81B
| $127M | 7.19% |
8,189,156
| – | – |
|
6
Coursera
COUR
$1.76B
| $109M | 6.17% |
12,867,769
| – | – |
|
7
Savara
SVRA
$1.09B
| $75.1M | 4.24% |
24,471,264
| – | – |
|
|
MBX
8
MBX Biosciences
MBX
$3.09B
| $66.6M | 3.76% |
3,614,486
| – | – |
|
9
CRISPR Therapeutics
CRSP
$4.7B
| $62.5M | 3.53% |
1,587,854
| – | – |
|
10
Monte Rosa Therapeutics
GLUE
$1.83B
| $53.4M | 3.01% |
7,692,298
| – | – |
|
11
Trevi Therapeutics
TRVI
$2.59B
| $48.8M | 2.76% |
11,370,376
| – | – |
|
12
Korro Bio
KRRO
$149M
| $41.5M | 2.34% |
1,090,793
| – | – |
|
13
Aurinia Pharmaceuticals
AUPH
$1.95B
| $35.6M | 2.01% |
3,969,834
| – | – |
|
|
14
CVRx
CVRX
$133M
| $25.7M | 1.45% |
2,026,083
-344,459
| -15% | -$4.25M |
|
|
ZBIO
15
Zenas BioPharma
ZBIO
$1.99B
| $21.4M | 1.21% |
2,613,948
| – | – |
|
|
NEUE
16
DELISTED
NeueHealth
NEUE
| $20.2M | 1.14% |
2,726,917
| – | – |
|
17
Gossamer Bio
GOSS
$100M
| $16.4M | 0.92% |
18,093,034
| – | – |
|
18
Celcuity
CELC
$4.05B
| $16.4M | 0.92% |
1,250,001
| – | – |
|
19
Phathom Pharmaceuticals
PHAT
$938M
| $15.9M | 0.9% |
1,960,169
| – | – |
|
20
Champions Oncology
CSBR
$77.4M
| $14.7M | 0.83% |
1,713,720
| – | – |
|
|
21
Oric Pharmaceuticals
ORIC
$1.19B
| $12.6M | 0.71% |
1,566,081
+66,081
| +4% | +$606K |
|
22
X4 Pharmaceuticals
XFOR
$379M
| $11M | 0.62% |
499,560
| – | – |
|
23
BuzzFeed
BZFD
$102M
| $10.2M | 0.58% |
3,833,473
| – | – |
|
|
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
| $10.2M | 0.58% |
6,467,802
| – | – |
|
25
Geron
GERN
$911M
| $9.83M | 0.55% |
2,776,409
| – | – |
|
Similar funds
NM
SLF
CCIA
SW
CGH
PWP
CIP
KOCAA
NEA Management Company's Q4 2024 Portfolio in Review
As of Q4 2024, NEA Management Company held 42 positions worth $1.77B, down 3.5% from $1.84B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Trading was light in Q4 2024: portfolio turnover was 2.4%. NEA Management Company opened no new positions and exited 1, leaving the 42-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 90% a quarter earlier, followed by Technology and Consumer Staples.
- NEA Management Company added most to Marker Therapeutics in Q4 2024, an estimated $1.96M increase.
- NEA Management Company's biggest Q4 2024 reduction was CVRx, cutting an estimated $4.25M.
- NEA Management Company fully exited Mynd.ai in Q4 2024, selling an estimated $165K.
- NEA Management Company's ten largest holdings make up 78% of its $1.77B portfolio in Q4 2024.
- NEA Management Company opened 0 new positions and closed 1 in Q4 2024.
- NEA Management Company's portfolio value fell 3.5% quarter-over-quarter to $1.77B.
Based on NEA Management Company's 13F filing for Q4 2024, filed 14 Feb 2025.